London Stock ExchangeLondon Stock Exchange

REG - Renalytix PLC - Notice of 2026 Annual General Meeting

Refinitiv閱讀2分鐘
RNS Number : 5698D Renalytix PLC 18 November 2026  

Renalytix plc

(“Renalytix” or the “Company”)

Notice of 2026 Annual General Meeting

LONDON and NEW YORK, 18 November 2026 - Renalytix plc RENX (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, confirms that the AGM of the Company will be held at 16 Columbus Walk, Brigantine Place, Cardiff, CF10 4BY on Friday 11 December 2026 at 10:30 a.m. (GMT).

The full Notice of AGM has been posted to shareholders who have not consented to receive electronic communications and is available on the Company website here: https://investors.renalytix.com/documents/.

As announced on 14 September 2026, the Company has extended its accounting reference date to 31 December 2026. As a result, the Company will publish audited accounts for the 18 month period ending 31 December 2026 by 30 June 2027, at which time an Annual General Meeting will be convened to lay them before shareholders.

For further information, please contact:

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker)

Tel: +44 (0)20 3470 0470

David Hignell / Jen Clarke (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Oberon Capital (Joint Broker)

Tel: +44 (0)20 3179 5300

Mike Seabrook / Heena Karani

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)

RenalytixTM RENX (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. Its KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.

Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States and United Kingdom medical systems, affecting approximately 15 million and 8 million people, respectively.

RenalytixTM has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  NOABRBRTMTJBBMF

閱讀全文
無限制訪問London Stock Exchange以及TradingView所有其他新聞來源的文章。